'Branded Generics' as a strategy to limit cannibalization of pharmaceutical markets

David Reiffen and Michael R. Ward ()
Additional contact information
David Reiffen: US Commodity Futures Trading Commission, USA, Postal: US Commodity Futures Trading Commission, USA

Health Economics, 2007, vol. 28, issue 4-5, pages 251-265

Abstract: This paper demonstrates how, by introducing a generic version of its previously patented product, a branded firm can influence the equilibrium in the generic segment of the market for the product. This in turn can increase the firm's profits from selling the branded version. We then use structural estimates from previous literature to calculate the magnitude of the effects in the generic and branded segments. Copyright © 2007 John Wiley & Sons, Ltd.

View list of references

Downloads: (external link)
http://hdl.handle.net/10.1002/mde.1339 Link to full text; subscription required (text/html)

Related works:
Working Paper: “BRANDED GENERICS” AS A STRATEGY TO LIMIT CANNIBALIZATION OF PHARMACEUTICAL MARKETS (2005)
Journal Article: 'Branded Generics' as a strategy to limit cannibalization of pharmaceutical markets (2007)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Access Statistics for this article

Health Economics is edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Series data maintained by Christopher F. Baum ().